ZZPZH(SH:600436) Zhong Guo Jing Ying Bao·2025-10-20 07:36Core Viewpoint - The financial performance of Pianzaihuang (片仔癀) in the first three quarters of 2025 shows significant declines in revenue and profit, primarily due to reduced sales in the pharmaceutical manufacturing sector and declining gross margins [1] Financial Performance Summary - Revenue for the first three quarters is approximately 7.442 billion yuan, a year-on-year decrease of 11.93% [1] - Net profit is about 2.129 billion yuan, down 20.74% year-on-year [1] - Deducted non-recurring profit is around 1.891 billion yuan, reflecting a 30.38% year-on-year decline [1] - Operating cash flow net amount decreased by 62.53% to approximately 487 million yuan [1] Quarterly Performance Summary - In the third quarter, revenue decreased by 26.28% year-on-year [1] - Net profit in the third quarter fell by 28.82% year-on-year [1] - Deducted non-recurring profit in the third quarter dropped by 54.6% [1] Business Segment Performance - Revenue from the pharmaceutical manufacturing sector decreased by 12.93% year-on-year [1] - Revenue from the pharmaceutical distribution sector declined by 8.45% year-on-year [1] - Revenue from the cosmetics sector fell by 23.82% year-on-year [1] - Gross margin for the pharmaceutical manufacturing sector decreased by 7.51 percentage points year-on-year [1] - Gross margin for the pharmaceutical distribution sector decreased by 4.19 percentage points year-on-year [1] - Gross margin for the cosmetics sector decreased by 1.28 percentage points year-on-year [1] Product-Specific Performance - Revenue from liver disease medications is approximately 3.88 billion yuan, a year-on-year decrease of 9.41% [1] - Revenue from cardiovascular medications is about 93.44 million yuan, reflecting a significant decline of 65.2% year-on-year [1]